BMRN — Biomarin Pharmaceutical Share Price
0.000.00%
Last trade - 00:00- $17.50bn
- $17.51bn
- $2.42bn
- 84
- 13
- 63
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 46.15 | ||
| PEG Ratio (f) | 1.13 | ||
| EPS Growth (f) | 69.4% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.53 | ||
| Price to Tang. Book | 3.92 | ||
| Price to Free Cashflow | 338.85 | ||
| Price to Sales | 7.23 | ||
| EV to EBITDA | 73.14 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.36% | ||
| Return on Equity | 3.51% | ||
| Operating Margin | 5.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,704.05 | 1,860.45 | 1,846.28 | 2,096.04 | 2,419.23 | 2,766.41 | 3,169.4 | 10.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +205.69 | +67.8 | +71.79 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Directors
- Jean-Jacques Bienaime CHM (67)
- Brian Mueller CFO (47)
- Henry Fuchs CEX (63)
- C. Greg Guyer EVP (59)
- G. Eric Davis EVP (50)
- Jeff Ajer EVP (58)
- Harold Bernstein SVP
- Richard Meier LED (61)
- Mark Alles IND
- Elizabeth Anderson IND (63)
- Willard Dere IND (67)
- Elaine Heron IND (72)
- Maykin Ho IND (68)
- Robert Hombach IND (55)
- V. Bryan Lawlis IND (69)
- David Pyott IND (66)
- Dennis Slamon IND (71)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 25th, 1996
- Public Since
- July 23rd, 1999
- No. of Shareholders
- 34
- No. of Employees
- 3,401
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 189,775,040
- Address
- 105 Digital Dr, NOVATO, 94949-8703
- Web
- https://www.biomarin.com/
- Phone
- +1 4155066700
- Auditors
- KPMG LLP
Upcoming Events for BMRN
Q1 2024 Biomarin Pharmaceutical Inc Earnings Call
Biomarin Pharmaceutical Inc Annual Shareholders Meeting
Biomarin Pharmaceutical Inc Annual Shareholders Meeting
Q2 2024 Biomarin Pharmaceutical Inc Earnings Release
Similar to BMRN
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
What is the Biomarin Pharmaceutical share price?
As of Today at 19:04 UTC, shares in Biomarin Pharmaceutical are trading at $92.22. This share price information is delayed by 15 minutes.
How has the Biomarin Pharmaceutical share price performed this year?
Shares in Biomarin Pharmaceutical last closed at $92.22 and the price had moved by -6.22% over the past 365 days. In terms of relative price strength the Biomarin Pharmaceutical share price has underperformed the S&P500 Index by -24.27% over the past year.
What are the analyst and broker recommendations for Biomarin Pharmaceutical?
The overall consensus recommendation for Biomarin Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Biomarin Pharmaceutical dividend yield?
Biomarin Pharmaceutical does not currently pay a dividend.
Does Biomarin Pharmaceutical pay a dividend?
Biomarin Pharmaceutical does not currently pay a dividend.
When does Biomarin Pharmaceutical next pay dividends?
Biomarin Pharmaceutical does not currently pay a dividend.
How do I buy Biomarin Pharmaceutical shares?
To buy shares in Biomarin Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biomarin Pharmaceutical?
As of the previous close price of $92.22, shares in Biomarin Pharmaceutical had a market capitalisation of $17.50bn.
Where are Biomarin Pharmaceutical shares listed?
Here are the trading details for Biomarin Pharmaceutical:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BMRN
What kind of share is Biomarin Pharmaceutical?
Based on an overall assessment of its quality, value and momentum Biomarin Pharmaceutical is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biomarin Pharmaceutical share price forecast for 2024?
The analyst consensus target price for shares in Biomarin Pharmaceutical is $109.70. That is 18.95% above the last closing price of $92.22.
Analysts covering Biomarin Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of $1.66 for the next financial year.
What is the trend in the Biomarin Pharmaceutical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomarin Pharmaceutical. Over the past six months, its share price has underperformed the S&P500 Index by -8.82%.
As of the last closing price of $92.22, shares in Biomarin Pharmaceutical were trading +3.66% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biomarin Pharmaceutical PE Ratio?
The Biomarin Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 46.15. The shares last closed at $92.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biomarin Pharmaceutical?
Biomarin Pharmaceutical's management team is headed by:
- Jean-Jacques Bienaime - CHM
- Brian Mueller - CFO
- Henry Fuchs - CEX
- C. Greg Guyer - EVP
- G. Eric Davis - EVP
- Jeff Ajer - EVP
- Harold Bernstein - SVP
- Richard Meier - LED
- Mark Alles - IND
- Elizabeth Anderson - IND
- Willard Dere - IND
- Elaine Heron - IND
- Maykin Ho - IND
- Robert Hombach - IND
- V. Bryan Lawlis - IND
- David Pyott - IND
- Dennis Slamon - IND